Plus Therapeutics (NASDAQ:PSTV) Given Buy Rating at HC Wainwright

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $8.00 price objective on the stock.

Separately, Ascendiant Capital Markets reduced their target price on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

Plus Therapeutics Trading Down 1.6 %

Shares of PSTV stock opened at $1.26 on Tuesday. The company has a market capitalization of $7.43 million, a price-to-earnings ratio of -0.50 and a beta of 0.69. Plus Therapeutics has a 1-year low of $1.12 and a 1-year high of $2.67. The stock’s fifty day simple moving average is $1.36 and its 200-day simple moving average is $1.62.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 3.28% of the stock is owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.